ZIM Laboratories, established in 1989, is a globally recognised provider of innovative Drug Delivery Solutions based in India. The company is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. The company has wholly owned subsidiaries (ZIM Laboratories FZE, UAE, SIA ZIM Laboratories Limited, Latvia, ZIM Health Technologies Limited, India and ZIM Thinorals Private Limited, India), subsidiary (ZIMTAS PTY Limited, Australia) and stepdown subsidiary (ZIM Scientific Office L.L.C, UAE), which are engaged in manufacturing & wholesale of pharmaceutical products, market research and research & development activities.

The company has a comprehensive portfolio across Pharmaceuticals and Nutraceuticals, offering Pre-Formulation Intermediates (PFI) and Finished Formulations (FF) across key therapeutic segments in Regulated, Pharmerging, and RoW markets.

Business area of the company 

The company is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India.

Products of the company

• Pre-Formulation Intermediates (PFI): The company’s Pre-Formulation Intermediates (PFI) portfolio comprises a diverse range of differentiated generic PFI, including pellets with varied release profiles, Directly Compressible (DC) granules and taste-masked powders customised for varied therapeutic applications. PFI strategy targets markets where laws/regulations restrict the direct import of Finished Formulations.
• Finished Formulations (FF): The company’s Finished Formulations portfolio includes assorted range of dosage forms, including tablets, capsules (with pellets offering varied release profiles), dry syrups, and Oral Thin Films - both Oro-dispersible and Oro-mucosal. FF segment partners with local distributors to market ZIM branded products while collaborating with regional companies to commercialise its offerings under their own Marketing Authorisations (MA), supported by ZIM’s dynamic dossiers.
• New Innovative Products (NIP): These next-generation complex molecules are designed to become First or Second Generics across diverse global markets, offering early market entry and a sustainable competitive edge in a highly dynamic pharmaceutical environment.
• Oral Thin Films: The company offers a diverse portfolio of Oral Thin Film Products designed for patient convenience, rapid absorption, and enhanced compliance.  Its innovative dosage forms include oral disintegrating strips that provide seamless drug delivery solutions for both pharmaceutical and nutraceutical applications.

Awards, accreditations and recognition 

• 2019 - Maharastra Best Employer Award.
• 2021 - Strategy Execution Award.
• 2022 - Confederation of Indian Industries (CII) Award.
• 2022 - Global Nagpur Awards.
• 2023 - Excellence In Pharma Global Business.

History and milestones

1989-2000: 

• Reinforced market position as a preferred supplier of Pharmaceutical products to government entities through tenders, supported by its WHO-GMP certified manufacturing plants.

2001-2012: 

• Established Pellets, Granules and Taste Masking Technology Platforms to expand portfolio and develop differentiated generic and higher-margin products.
• Extended international presence across Middle East and North Africa (MENA) regions.
• Developed ‘Proof-of-Concept’ for Oral Thin Films and Nanotechnology to drive next-generation innovation.

2013-2017:

• Raised funding through private equity to fuel business growth.
• Prioritised focus on high-margin businesses by reducing exposure to deemed exports and low-margin government contracts.
• Upgraded manufacturing facilities to align with EU-GMP standards, strengthened team strength and improved processes.
• Set up a new WHO-GMP approved Oral Thin Films (OTF) facility, successfully commercialised OTF products.
• Entered new markets, including Southeast Asia, Latin America (LatAm), CIS, and Africa, while consolidating market positions in Sri Lanka, South Asia and MENA.
• Developed a robust pipeline of new products, enhanced dossier filings and secured product registrations under the ZIM brand.
• Launched Thinoral (Patented Oral Thin Film technology) as an alternate drug delivery platform for prescription and OTC products across RoW/Pharmerging Markets and EU markets.

2018-2025:

• Expanded the generic finished formulations business through product registrations, marketing partnerships and regular product launches across MENA, SE Asia, LatAm and CIS regions.
• Strengthened R&D team competencies to build new combination generic Pharmaceuticals for Pharmerging and select Developed Markets.
• Listed on BSE and NSE.
• Introduced 10 New Innovative Products (NIPs) for Key Developed and Pharmerging Markets.
• Enhanced manufacturing capacity, including a dedicated NIP warehouse and a potential dedicated Greenfield Nutraceuticals plant.
• Set up ZIMTAS PTY LTD - ZIM’s subsidiary in Australia (2022) for product registration, marketing and distribution in Australia and New Zealand.
• Secured EU re-accreditation (Portugal) and NSF re-accreditation for ODS Dietary Supplements.
• Started a scientific office in the UAE (Nov 2024) to support registration and marketing of Pharmaceutical and Nutraceutical products and drive expansion across the MENA region.
• Completion of two major CapEx projects - a Nutraceutical Suite in FY25 to support future growth initiatives.
• Secured EU Marketing Authorisations for Azithromycin Oral Suspension and Dimethyl Fumarate (under the New Innovative Products (NIP) category).
• ZIM’s co-development partner, Neuraxpharm, obtained an EU-wide Marketing Authorisation for Buprenorphine Sublingual Films.
• The company received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a Fixed Dose Combination (FDC) of Naproxen Delayed Release and Esomeprazole Capsules.
• The company completed a preferential allotment facilitating strategic capital infusion to support its growth and expansion objectives.